Introduction {#Sec1}
============

The nuclear receptor superfamily of transcriptional regulators includes a number of receptors for lipid hormones including oestrogen, androgen, thyroid hormone and the corticosteroids. Several other receptors in this family are for lipid hormone-like ligands; this includes vitamin D, which through its activation and release by the kidney functions as a paracrine hormone (Bell [@CR5]) while vitamin A through its active metabolite retinoic acid (RA) functions as a locally released paracrine or autocrine hormone, acting via retinoic acid receptors (RARs). The retinoid X receptors (RXRs) can heterodimerise with vitamin D receptor and RARs as well as the thyroid hormone receptors (Shaffer and Gewirth [@CR59]; Glass [@CR28]). Vitamin A is stored in the body as retinyl esters which are hydrolysed and released as retinol to maintain a constant 1 μM concentration of retinol in the plasma, bound to retinol-binding protein (Blomhoff [@CR7]). Cells actively take up retinol and oxidise this to RA which diffuses locally to activate nearby cells (Blomhoff [@CR7]).

This system is essential for development of many organ systems in the embryo (Sporn et al. [@CR63]) including the CNS (McCaffery et al. [@CR41]), but its importance for the postnatal brain has only been relatively recently recognised. The hippocampus had been an area of particular focus in this research (McCaffery et al. [@CR42]) where RA performs roles with parallels to its function in the developing brain, modulating neuronal plasticity. Hippocampal function in learning and memory is dependent on plastic changes in synaptic strength, numbers of synapses and neurons, all of which can be modified and in which RA plays a role (McCaffery et al. [@CR42]). The number of granule neurons in the dentate gyrus is modified through regulated neurogenesis (Alvarez-Buylla and Lim [@CR2]) and this can be controlled by RA in a biphasic fashion with both a deficiency (Jacobs et al. [@CR32]) and excess (Crandall et al. [@CR20]) leading to diminished neurogenesis and decline in performance in a radial maze (Crandall et al. [@CR20]). When rats are deficient in vitamin A, modification of synaptic strength through long-term potentiation is reduced together with their ability to perform in a radial maze (Misner et al. [@CR46]; Cocco et al. [@CR16]). Further, when the RARs are functionally removed by mutation in mice then this results in deficits in both long-term potentiation and long-term depression as well as the expected deficits in performance in hippocampal-dependent learning and memory tasks (Chiang et al. [@CR15]). More recently it has been shown that synaptic scaling, necessary for overall homeostatic regulation of a neuron's synapses requires RA to maintain this stability, surprisingly not through RARs regulation of transcription but rather though modification of translation (Aoto et al. [@CR3]; Poon and Chen [@CR52]).

The RARs that mediate these events are distributed throughout the mammalian brain as has been shown extensively in the mouse and rat (Ruberte et al. [@CR55]; Zetterstrom et al. [@CR70], [@CR71]; Krezel et al. [@CR36]) and in limited studies in the human (Rioux and Arnold [@CR53]). Also essential are the enzymes that synthesise RA from retinol, performing this oxidation in two steps, the first step catalysed by ubiquitous retinol dehydrogenases, the final step by tissue specific retinaldehyde dehydrogenases (RALDHs) (Mey and McCaffery [@CR45]). Both steps are essential, but in the rodent brain there is reported to be only localised RALDH expression in certain cortical neurons as well as the meninges surrounding the brain (Wagner et al. [@CR68]; Luo et al. [@CR38]). Although cultured neurons from the hippocampus express the RALDHs (Rioux and Arnold [@CR53]), there is little expression of these enzymes in vivo and it is hypothesised that RA is derived from the meninges by diffusion (Sakai et al. [@CR57]). RA levels, at least in the mouse hippocampus, must be low and the RA-regulated hippocampal events described in the mouse may require only very low levels of this paracrine hormone. The situation in the human hippocampus, however, has been unexplored. This study confirms that RALDH levels are very low in mouse neurons but, to the contrary, qPCR detects high levels of RALDH transcript in the human hippocampus and corresponding strong expression of RALDH protein in hippocampal neurons. This implies an essential function of RA in the human hippocampus and, from its described roles in the rodent hippocampus of regulation of neuronal plasticity, this is potentially its role in the human.

Methods {#Sec2}
=======

Preparation of tissues {#Sec3}
----------------------

The present study was approved by the Ethics Committee of Universidade Metropolitana de Santos, SP, Brazil, and by the Brazilian Health Research Committee on April 4th 2011, under the number CONEP 16168, documents registered under the number 25000.169694/2010-18. Caudal human hippocampi from six male individuals aged 55 years or less, who did not present any neurological or psychiatric disease, were collected during necropsy procedures. Brains from individuals whose death was related to head trauma, and extensive infection, toxic, anoxic or metabolic injuries were excluded from this study. Samples from the hippocampus, measuring typically 0.5 cm^3^, were fixed in 10% buffered (NaH~2~PO~4~ and Na~2~HPO~4~) formalin within 24 h from death and placed in paraffin blocks within the following 24 h. Other samples from the same areas were collected in RNAlater RNA Stabilization Reagent (Qiagen, Venlo, The Netherlands) and stored at 4°C for qPCR or were freshly frozen for western blot analysis. Mouse tissues were from adult male C57Bl6 mice aged 3 months (*n* = 3) bred from an in-house colony that were kept on a 12L:12D light cycle. These animals were perfusion fixed using 4% paraformaldehyde. All animal procedures were carried out in accordance with Home Office regulations and local ethics committee guidelines.

Western blotting {#Sec4}
----------------

Human hippocampal protein was extracted in 0.01 M phosphate buffer containing a protease inhibitor cocktail (Sigma) using mechanical homogenisation and three freeze--thaw cycles. Homogenates were centrifuged 10 min at 12,000 rpm at 4°C. Total protein levels in each sample were quantified by the BCA assay (Pierce) and loaded onto a 12% SDS-PAGE mini-gel, 50 μg total protein per lane. After separation the proteins were transferred onto a Hybond™-ECL nitrocellulose membrane (GE Healthcare) using a Mini Trans-Blot Cell (Bio-Rad) and loading was checked with Ponceau-S (Sigma). Membranes were probed with the primary antibodies that were to be used for immunohistochemistry of the RALDH enzymes; rabbit anti-RALDH1 (Abcam 1:3,000), rabbit anti-RALDH2 (1:10,000) or rabbit anti-RALDH3 (1:10,000) overnight. Staining was detected using a secondary HRP anti-rabbit antibody (Sigma 1:5,000) and enhanced chemiluminescence (Millipore) incubated for 5 min followed by exposure to X-ray film (Thermo Fisher Scientific).

Immunohistochemistry {#Sec5}
--------------------

The samples were sectioned at 7 μm, onto A380-bond slides (Electron Microscopy Sciences, Hatfield PA 19440, USA) and dried overnight at 37°C. Paraffin was removed from tissue samples with xylene and was rehydrated through decreasing ethanol concentrations (100, 95, 80 and 70%). Antigen retrieval was achieved by microwaving samples for 10 min in sodium citrate buffer, pH 6.0. Samples were allowed to cool on the bench for 20 min and were then washed in 1 × PBS pH 7.4, containing 1% Tween 20 (Sigma) and 1% pooled human serum (BioSera) (from now on referred as the PBS solution). From this stage, immunohistochemistry was then carried out with two different procedures depending on the staining method.

Immunohistoperoxidase detection {#Sec6}
-------------------------------

The samples were incubated with 3% H~2~O~2~ in methanol for 10 min to block endogenous peroxidases and subsequently washed with 1 × PBS. Avidin--Biotin (Vector Labs) blocking was performed to reduce non-specific binding. Primary antibodies used were rabbit anti-RALDH1 (1:300, Abcam), rabbit anti-RALDH2 \[1:2,000, (Berggren et al. [@CR6])\], rabbit anti-RALDH3 \[1:3,000, (Wagner et al. [@CR68])\], rabbit anti-RARα (1:300 Santa Cruz), rabbit anti-RARβ (1:300 Santa Cruz Biotechnology) and rabbit anti-RARγ (1:300 Santa Cruz Biotechnology). RALDH1 was raised against a rat peptide and has been shown to react with multiple tissues including human according to the manufacturer's description. RALDH2 and 3 were raised against whole protein and the RALDH2 antibody has been shown to recognise the human protein (Spiegl et al. [@CR62]). All the RAR antibodies are raised against human epitopes and react with human tissue (Meng et al. [@CR44]; Lu et al. [@CR37]; Alique et al. [@CR1]). After washing with 1 × PBS, the tissue was incubated with biotinylated secondary antibodies (Sigma) for 1 h at room temperature. Subsequently, the slides were washed with the PBS solution and incubated for 1 h with Vecstatin ABC Elite (Vector Labs). After further washing, the sections were exposed to 0.05% 3,3′-diaminobenzidine (Sigma) diluted 0.1% in PBS, to visualise antibody staining. Nuclei staining was carried out with haematoxylin staining, and tissue was dehydrated through sequential ethanol concentrations followed by xylene before mounting with DPX (Sigma).

Immunofluorescent detection {#Sec7}
---------------------------

Samples were incubated for 1 h, at room temperature, with blocking solution (1 × PBS pH 7.4 containing 0.3% Tween 20, 5% normal goat serum, 5% bovine serum albumin and 5% pooled human serum (Makitie et al. [@CR39]) tissue was incubated with the primary antibody diluted in blocking solution and incubated overnight at 4°C. Primary antibodies and incubation procedures were the same as described above. The primary antibody used in double-labelling experiments to identify neurons was chicken anti-MAP2 (1:500 Millipore).

After incubation, the slides were washed in the PBS solution. The tissue was then incubated with the secondary fluorescent antibody \[anti-rabbit 1:300 (Alexa Fluor, Invitrogen) or anti-chicken 1:400 (DyLights, Stratech)\] diluted in the PBS solution, for 1 h, at room temperature. Slides were washed in the PBS solution and incubated for 1 min with 10% Sudan Black (Acros Organics) made up in 70% isopropyl alcohol to reduce auto-fluorescence (Schnell et al. [@CR58]; Neumann and Gabel [@CR47]). The slides were then thoroughly washed in distilled water and mounted with mounting medium containing 1,4-diazabicyclo\[2.2.2\]octane (DABCO, Sigma) and bisbenzimide (Sigma).

Quantitative PCR {#Sec8}
----------------

Total RNA was extracted from hippocampal samples using a RNeasy mini kit (Qiagen) with on column DNase treatment (Qiagen). RNA was quantified using a Nanodrop spectrophotometer (Thermo Scientific). cDNA was synthesised using High Capacity RNA to cDNA Master Mix (Applied Biosystems). qPCR analysis was performed using SensiMix SYBR (Bioline) to assess the presence or absence of RALDH and RAR gene expression in human (*n* = 3) samples. Primers were designed for human analysis using human RNA sequences obtained from the NCBI gene database. The primer sequences were as follows: RALDH1 (F: CAAGGCAGTGAAGGCCGCAAGA, R: ATTGACTCCATTGTCGCCAGCAGC), RALDH2 (F: CACTGAGCAGGGTCCCCAGATTGA, R: AACCCCTTTCGGCCCAGTCCT), RALDH3 (F: CGCAACCTGGAGGTCAAGTTCACC, R: AGCCTTGTCCACGTCGGGCTTA), RARα (F: GAGGGCTGTAAGGGCTTCTTCCG, R: TGAGCTCGCCCACCTCAGGC), RARβ (F: GCTTAATCTGTGGAGACCGCCAGG, R: TGTGAGGCTTGCTGGGTCGT), RARγ (F: GGGGCATCAGCACTAAGGGAGCT, R: AGGCATTGGGGTGGGGACCA) and GAPDH (F: TCTTTTGCGTCGCCAGCCGA, R: AGTTAAAAGCAGCCCTGGTGACCA) was used as an internal control standard for all human samples. Standard curves and blank controls were run for all genes. Samples were run on a LightCycler^®^ 480 (Roche) and analysed using LightCycler^®^ SW 1.5 software. Analysis was performed using relative quantification and the Roche's E-method of quantification which uses standard curve derived efficiencies.

Cell counting {#Sec9}
-------------

Photographs of slides were taken using a Nikon Eclipse E400 microscope and images captured with a QICAM Fast 1394 (QImaging) camera and analysed by Image J cell counter plugin (Image Processing and Analysis in JAVA; public domain, developed at the National Institutes of Health; NIH, USA). The total number of cells was determined by counting of cell nuclei fluorescently labelled with bisbenzamide (blue) while the number of immunolabelled cells was determined by counting of cells fluorescently labelled with either Alexa Fluor 546 (red, used for RAR or RALDH) or Alexa Fluor 488 (green, used for MAP2)-labelled secondary antibody. For each antibody of interest 100 cells, either nuclear stained (all cells) or MAP2 stained (neurons only) were counted and of these the number of cells positive for the RAR or RALDH antibodies was counted. For each antibody 6 individual samples were quantified in 3 different sections per individual and between 3 and 5 fields of view were counted. Average values of the counts were taken and standard error of the mean shown. Data were analysed using One-way ANOVA with Tukey post-hoc testing.

Results {#Sec10}
=======

Expression of retinoic acid synthetic enzymes in the mouse and human dentate gyrus {#Sec11}
----------------------------------------------------------------------------------

The RALDH enzymes are responsible for the final oxidative step to synthesise RA from vitamin A. Antibodies for these proteins have been extensively used in rodent studies; however, limited information is available as to their specificity in humans. Western blotting of human hippocampus showed that all three antibodies directed against the RALDH proteins detected proteins of the appropriate molecular weight (Fig. [1](#Fig1){ref-type="fig"}a); single bands were detected for RALDH1 (54 kDa) and RALDH3 (56 kDa), whereas two bands were evident for RALDH2 (55 and 36 kDa) as seen for rodent tissue and the smaller protein may represent a proteolytic fragment of the larger. In the mouse hippocampus these enzymes cannot be detected in neurons by immunohistochemistry (Wagner et al. [@CR68]), nor their transcripts by in situ hybridization (Allen Brain Atlas <http://www.brain-map.org/>) and the primary source for the hippocampus is likely the meninges (Sakai et al. [@CR57]). This low expression is confirmed here with DAB immunohistochemistry in which the mouse hippocampus is negative for RALDH3 and RALDH1 and 2 are only present in the meninges (Fig. [1](#Fig1){ref-type="fig"}b--d). Using the same immunohistochemical technique however, the human hippocampus contrasted markedly with all three RALDH proteins expressed in a proportion of cells in the dentate gyrus of the hippocampus, illustrated in Fig. [1](#Fig1){ref-type="fig"}e--g, demonstrating the capacity of these neurons to synthesise RA.Fig. 1Prevalence of RALDH proteins in the mouse and human hippocampus. The specificity of the RALDH antibodies to their respective proteins in the human hippocampus was verified with western blotting, identifying RALDH1 (54 kDa), RALDH2 (55 kDa) and RALDH3 (56 kDa) (**a**). 3,3′-diaminobenzidine (DAB) immunohistochemistry was used to determine differing expression patterns for the RALDH protein in the mouse and human hippocampus. The mouse hippocampus including the dentate gyrus (DG) showed no expression of any of the RALDHs (**b**--**d**), but RALDH1 and RALDH2 were expressed in the underlying meninges (indicated by *arrows*). In contrast the human hippocampus expressed all three RALDH enzymes in cells of the dentate gyrus (**e**--**g**).*Scale bars***b**--**d** 50 μm, **e**--**g** 40 μm

Immunofluorescent detection of retinoic acid synthetic enzymes and receptors in the human dentate gyrus {#Sec12}
-------------------------------------------------------------------------------------------------------

To confirm that the intense immunolabelling of RALDHs in the dentate gyrus was not the result of non-specific immunoperoxidase labelling, an immunofluorescent technique was employed based on that of Makitie et al. ([@CR39]) providing very sensitive and specific staining while effectively quenching autofluorescence. This was performed with hippocampi from six adult individuals of age less than 55 years and representative images are shown of RALDH1 (Fig. [2](#Fig2){ref-type="fig"}a), RALDH2 (Fig. [2](#Fig2){ref-type="fig"}b) and RALDH3 (Fig. [2](#Fig2){ref-type="fig"}c), demonstrating immunolabelling in cells of the dentate gyrus. Double labelling with the neuronal marker MAP2 demonstrated that the RALDHs are present in neurons, shown for RALDH1 expressed predominantly in its typical cytoplasmic location (Fig. [2](#Fig2){ref-type="fig"}d).Fig. 2Elements of the RA synthesis and signalling pathway in the human dentate gyrus. A sensitive immunofluorescence technique used for human hippocampal sections showed differing distributions of the RALDH proteins in the dentate gyrus (DG, **a**--**c**). All three proteins were present in a proportion of cells with extensive labelling for RALDH2 (**b**) and RALDH3 (**c**) with less labelling seen for RALDH1 (**a**). An example of immunofluorescence double labelling for RALDH1 with the neuronal marker MAP2 showed predominantly cytoplasmic (shown by *arrow*) but also some nuclear localization in neurons (**d**), the*inset* shows the separate colour channels for the main merged image. Immunofluorescence was used to detect the presence of RARα, β and γ in the human hippocampus. Positive staining was seen for all three receptors (**e**--**g**) in the dentate gyrus. Greatest staining was observed for RARβ (**f**) followed by RARα (**e**) and RARγ (**g**). Using immunofluorescence double labelling with MAP2, RARγ is shown to have a nuclear localization (shown by *arrow*) (**h**), the*inset* shows the separate colour channels for the main merged image. Quantitative real-time PCR showed that all RALDH genes were expressed in the hippocampus (**i**) and RALDH2 was particularly prominent. Similarly, all three RARs transcripts were present in the hippocampus (**j**) in particular RARβ. All expression levels are shown relative to the expression of the housekeeping gene β-actin. SEM are shown for an *n* = 3.*Scale bars***a**--**c** and **e**--**g** 40 μm, **d** and **h** 40 μm

The importance of RA signalling in the hippocampus has been implied in the rodent from RA receptor expression \[reviewed (McCaffery et al. [@CR42])\] but very few studies have explored receptor expression in the human. All three RARs, α, β and γ (Fig. [2](#Fig2){ref-type="fig"}e--g) were present in the human dentate gyrus. Double labelling with MAP2 showed neuronal localization as shown for RARγ present in both the nucleus and cytoplasm implying possibly both genomic and non-genomic function (Fig. [2](#Fig2){ref-type="fig"}h) (as discussed below).

qPCR analysis of RALDHs and RARs was performed on samples of caudal hippocampus from three subjects to determine the expression of their respective mRNA transcripts. The RALDHs were identified within 23 cycles indicating substantial levels of all three enzymes with RALDH2 being the most prominently expressed (Fig. [2](#Fig2){ref-type="fig"}i). qPCR analysis of transcript expression by qPCR found RARα, β and γ were expressed in the hippocampus with RARβ being the most prominent (Fig. [2](#Fig2){ref-type="fig"}j).

Expression of retinoic acid synthetic enzymes and receptors in neurons of the human hippocampal CA1 subfield {#Sec13}
------------------------------------------------------------------------------------------------------------

RALDH1, 2 and 3 were also present in neurons of the cornu ammonis (CA) subfields of the hippocampus as determined by double-labelling with MAP2 (Fig. [3](#Fig3){ref-type="fig"}a--c) and compared with a negative control lacking RALDH primary antibody (Fig. [3](#Fig3){ref-type="fig"}d). The enzymes were predominantly localised to the cytoplasm and were also present in some cell processes, while some cells also showed nuclear localization as has been recently shown in rodent astrocytes (Wang et al. [@CR69]).Fig. 3RALDH1, 2 and 3 are present in neuronal cells of the human CA1 hippocampal subfield. Double labelling immunofluorescence with the neuronal marker MAP2 showed RALDH1 (**a**), RALDH2 (**b**) and RALDH3 (**c**) proteins present in neurons of CA1. Each image panel shows the separate colour channels as smaller inserts to the left of the main merged image. The distribution of these proteins is predominantly cytoplasmic but with some expression in the nucleus (as shown by *arrows* in **a**--**c**). A negative control sample that was stained with MAP2 but no RALDH antibody showed absence of background staining (**d**). All*scale bars* 20 μm

Nuclear RARs regulate gene expression in a ligand-activated fashion (Chambon [@CR13]) while more recently cytoplasmic RARs have been demonstrated to perform non-genomic roles, regulating various kinases (Rochette-Egly and Germain [@CR54]) as well as protein translation (Chen et al. [@CR14]; Poon and Chen [@CR52]). Each RAR showed a distinctive subcellular distribution (Fig. [4](#Fig4){ref-type="fig"}a--c) compared with the negative control without RAR primary antibody (Fig. [4](#Fig4){ref-type="fig"}d). RARα was present in the nucleus as well as showing a perinuclear distribution (Fig. [4](#Fig4){ref-type="fig"}a), RARβ was identified in the cell nucleus and cytoplasm (Fig. [4](#Fig4){ref-type="fig"}b) and RARγ was found predominantly in the nucleus (Fig. [4](#Fig4){ref-type="fig"}c). No RAR staining was observed in the cell processes, contrasting with in vitro cultured neurons that can show strong expression within neuronal processes (unpublished observation).Fig. 4Subcellular distribution of RARα, RARβ and RARγ in human CA1 neurons. RARs were shown to co-localise with neurons as determined by MAP2 double-labelling (**a**--**c**). Each image panel shows the separate colour channels as smaller inserts to the left of the main merged image. RARα protein was observed in the nucleus and the perinuclear region (as shown by *arrows*, **a**), RARβ was observed both in the nucleus and the surrounding cytoplasm of neurons (as shown by *arrow*, **b**) and RARγ was detected in neuronal nuclei (as shown by *arrows*, **c**). A negative control sample that was stained with MAP2 but no RAR antibody was run alongside the positive samples (**d**). All*scale bars* 20 μm

Relative number of neurons in the dentate gyrus and CA1 expressing retinoic acid synthetic enzymes and receptors {#Sec14}
----------------------------------------------------------------------------------------------------------------

Numbers of MAP2 positive neurons in the dentate gyrus and CA1 subfields expressing either RALDHs or the RARs were counted to determine the relative distribution of these components of the RA-signalling pathway. RALDH1 was significantly less expressed in the dentate gyrus (56%), than RALDH2 (84%, *P* \< 0.001) or RALDH3 (77%, *P* \< 0.01) (Fig. [5](#Fig5){ref-type="fig"}a, b). A significantly smaller proportion of neurons in CA1 expressed these enzymes compared with the dentate gyrus (Fig. [5](#Fig5){ref-type="fig"}a). Similarly, the RA receptors were also expressed in significantly (*P* \< 0.001) fewer neurons in the CA1 subfield compared with the dentate gyrus (*P* \< 0.001) (Fig. [5](#Fig5){ref-type="fig"}b).Fig. 5Quantification of neuronal RALDH and RAR expression. Neurons double labelled for MAP2 and RALDH1--3 or MAP2 and RARα--γ were quantified in the dentate gyrus and CA1 sub-regions of the human hippocampus. A comparison of the number of RALDH positive neurons in the dentate gyrus showed that RALDH1 was significantly less expressed than RALDH2 and RALDH3 in MAP2-positive cells (**a**). When RALDH positive cells were compared between the hippocampal sub-fields there were significantly more stained neurons in the dentate gyrus than in CA1. Evaluation of RAR-positive neurons showed no differences within sub-fields but a significant difference between areas, with CA1 containing less RAR-positive MAP2 cells than the dentate gyrus (**b**). \*\**P* \< 0.01 and \*\*\**P* \< 0.001

Discussion {#Sec15}
==========

This study shows the strong expression in the human hippocampus of the components required for RA signalling; both the enzymes necessary for RA synthesis as well as the receptors required to respond to the signal. This is the first report to describe the RA synthetic enzymes in the human brain, finding varying levels of the three subtypes, RALDH1, 2 and 3, in hippocampal neurons. Given that the RALDH expression correlates very well with localised regions of RA synthesis (Niederreither et al. [@CR49]; Swindell et al. [@CR65]; Wagner et al. [@CR68]) and mutation of RALDHs completely eliminate RA synthesis \[as reviewed (Duester [@CR23])\] this implies these neurons are capable of generating RA. This contrasted to the complete lack of these enzymes in mouse hippocampal neurons, the probable source of RA being the nearby meninges (Sakai et al. [@CR57]). Of the receptors, RARα, β and γ could be detected in neurons in the dentate gyrus while a smaller proportion of neurons within CA1 expressed these receptors. This contrasts with mouse in which RARγ is the only receptor present in the dentate gyrus while in the CA1/CA3 subfields RARα and γ are expressed as described by Krezel et al. ([@CR36]). They describe the importance of examining RA receptor protein expression, as opposed to transcript, because of the surprisingly large discrepancies in certain regions of the brain presumably indicating extensive post-transcriptional regulation of the RA receptors (Krezel et al. [@CR36]). Very few papers have described RA receptors in the human brain, although Rioux and Arnold reported RARα and RARγ in only approximately 12% of granule neurons and RARα in some neurons of the hippocampal subfields (Rioux and Arnold [@CR53]). However, this paper used immunohistochemistry in the absence of antigen retrieval which is likely to provide only low sensitivity of detection in contrast to the high sensitivity of the immunofluorescent technique employed in this study, comparable to the methods used in rodent model species. The high expression of both receptors and RA synthetic enzymes compared with mouse models implies a crucial function in the human hippocampus. One recently discovered potential function for RA in the hippocampus is regulation of synaptic scaling.

Synaptic scaling is one mechanism providing balance to neuronal firing rates, maintaining homeostasis within neuronal networks (Turrigiano [@CR67]). The regulatory system includes transient synthesis and insertion of AMPA receptors at synapses (Ju et al. [@CR34]; Sutton et al. [@CR64]). Regulated RA synthesis in neurons has been proposed as a mechanism to control this process; when the action potential of cultured neurons is blocked with tetrodotoxin together with a block of NMDA receptors with aminophosphonovalerate this induces synaptic scaling (Ju et al. [@CR34]; Sutton et al. [@CR64]) proposed to be mediated by a local increase in RA synthesis promoting local translation of AMPA receptor (Aoto et al. [@CR3]). In contrast to the majority of RA's actions through transcriptional regulation via RA receptors in the nucleus, this is a non-genomic mechanism in which RARα directly interacts with specific mRNAs to inhibit translation, this inhibition being released on binding to RA (Poon and Chen [@CR52]) in a process that also involves the fragile X protein FMRP (Soden and Chen [@CR61]). Interestingly, in the human hippocampus it is RARβ detected in the cytoplasm, while RARα and γ tend to be restricted to the nucleus; thus RARβ may be more crucial for such non-genomic functions. It is proposed that RALDH1 catalyses RA synthesis for synaptic scaling and high levels of RALDH1 are reported in cultured mouse hippocampal neurons (Aoto et al. [@CR3]). However, this new study and those of others (Wagner et al. [@CR68]) show that none of the RALDHs are strongly expressed in endogenous rodent hippocampal neurons, and these plastic processes must rely on only low levels of RA. We now show, however, that human neurons in situ show strong RALDH expression and synaptic scaling may thus be mediated by endogenous RA in the human hippocampus.

Controversy has developed over the effect of RA on the human brain because of the use of the 13-cis isomer of RA as the active agent in the acne drug isotretinoin. Although it is clear that there are a number of adverse effects in the CNS, the most common being headache (Bremner and McCaffery [@CR9]), many studies have linked the onset of depression with such treatment (Hazen et al. [@CR30]; Gatti and Serri [@CR27]; Jick et al. [@CR33]; Bremner et al. [@CR10]; Azoulay et al. [@CR4]) while other studies have found the contrary (Rubinow et al. [@CR56]; Ng et al. [@CR48]; Cohen et al. [@CR17]; Bozdag et al. [@CR8]; McGrath et al. [@CR43]). One profound problem in resolving this quandary is the difficulty in untangling the psychosocial influence of severe acne with the potential effects of the drug. Understanding the biological effects of RA on the brain is thus crucial. Rodent animal studies have shown the requirement of retinoids on functions as diverse as learning and memory performance (Etchamendy et al. [@CR24]), sleep (Maret et al. [@CR40]) and mesolimbic system-driven locomotion (Krezel et al. [@CR35]); deficits in all these systems result from a reduction in RA signalling. Not just deficiency but excess RA also disrupts RA signalling and treatment of mice with RA at the same dose used for acne treatment alters hippocampal neurogenesis, leading to decreased numbers of newborn neurons together with a reduced performance in the radial maze test (Crandall et al. [@CR20]). Similarly, treatment of rats with RA also leads to degradation in performance in learning and memory tests (Dopheide and Morgan [@CR22]) while others have reported an increase in anxiety like behaviour (Cai et al. [@CR12]). Despite these multiple effects by RA on the CNS, its influence on depression-like behaviour in the rodent is less clear with several studies pointing to an increase in some depressive-like behaviours (O'Reilly et al. [@CR51]; Trent et al. [@CR66]) with others studies showing no change (Ferguson et al. [@CR25], [@CR26]). One possible explanation for variation in result between studies is the baseline of RA signalling---RA exhibits a U-shaped curve in its toxicity, with detrimental effects in both deficiency and excess and endogenous levels crucially influence the possible harmful effect of an exogenous dose. The high levels of RA-synthesizing enzymes in the human hippocampus likely results in a very different response of the CNS to drugs such as isotretinoin compared with rodent models, where the expression of these enzymes is much lower. This needs to be taken into account when it comes to interpretation of these models but almost certainly means that the human CNS will have an altered sensitivity to RA. Further, the likelihood of high levels of RA synthesis in the human hippocampus will have consequences for the reliance of the brain on vitamin A. It is known that vitamin A levels in the brain can decline with age (Craft et al. [@CR19]) while the carotenoid form of vitamin A is protective against cognitive decline (Grodstein et al. [@CR29]) and retinoic acid has been reported to provide protection from Alzheimer's disease (Corcoran et al. [@CR18]; Ono et al. [@CR50]; Husson et al. [@CR31]; Brouillette and Quirion [@CR11]; Donmez et al. [@CR21]; Shudo et al. [@CR60]). The human hippocampus may have a lower resilience to a decline in vitamin A than rodent model species.
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